Perceptive Advisors LLC grew its holdings in Xencor Inc (NASDAQ:XNCR) by 1.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,313,095 shares of the biopharmaceutical company’s stock after purchasing an additional 20,000 shares during the quarter. Xencor comprises 1.0% of Perceptive Advisors LLC’s portfolio, making the stock its 27th biggest holding. Perceptive Advisors LLC owned approximately 2.80% of Xencor worth $28,783,000 at the end of the most recent quarter.
Other large investors have also modified their holdings of the company. Virginia Retirement Systems ET AL grew its position in shares of Xencor by 10.0% in the third quarter. Virginia Retirement Systems ET AL now owns 76,200 shares of the biopharmaceutical company’s stock valued at $1,747,000 after purchasing an additional 6,900 shares during the last quarter. State Street Corp grew its position in shares of Xencor by 11.1% in the second quarter. State Street Corp now owns 1,103,455 shares of the biopharmaceutical company’s stock valued at $23,295,000 after purchasing an additional 110,474 shares during the last quarter. GSA Capital Partners LLP grew its position in shares of Xencor by 87.4% in the third quarter. GSA Capital Partners LLP now owns 72,700 shares of the biopharmaceutical company’s stock valued at $1,666,000 after purchasing an additional 33,900 shares during the last quarter. Point72 Asset Management L.P. acquired a new stake in shares of Xencor in the third quarter valued at about $1,146,000. Finally, Artal Group S.A. acquired a new stake in shares of Xencor in the third quarter valued at about $2,292,000. 79.49% of the stock is currently owned by institutional investors.
In related news, insider Edgardo Baracchini, Jr. sold 10,000 shares of Xencor stock in a transaction dated Friday, March 2nd. The stock was sold at an average price of $29.60, for a total transaction of $296,000.00. Following the sale, the insider now directly owns 10,000 shares of the company’s stock, valued at $296,000. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, major shareholder John S. Stafford III bought 6,215 shares of the firm’s stock in a transaction that occurred on Tuesday, December 12th. The shares were purchased at an average cost of $20.72 per share, for a total transaction of $128,774.80. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 65,000 shares of company stock worth $1,865,950. 4.14% of the stock is owned by company insiders.
Shares of Xencor Inc (NASDAQ:XNCR) opened at $32.72 on Monday. Xencor Inc has a 1 year low of $18.55 and a 1 year high of $33.00.
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.